Non-interventional Study With Azacitidin (Vidaza®)

Inclusion Criteria: * Patients who are not eligible for haematopoietic stem cell transplantation, who are at least 18 years old (no age limit to top) and who have one of the following diseases: * myelodysplastic syndrome (MDS) with intermediate risk 2 or high risk according to the International Prognostic Scoring System (IPSS) * chronic myelomonocytic leukemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder * acute myeloid leukemia (AML) with 20-30% blasts and multilineage dysplasia according to classification of the World Health Organisation (WHO). Exclusion Criteria: * Contraindication according to the summary of product characteristics of Vidaza® * Signed patient informed consent form is not available * Patients with advanced malignant hepatic tumors * Pregnant or nursing women, men and women (of childbearing age) who are unwilling to apply a reliable method of contraception during and up to three months after treatment with Azacitidine * Necessary or planned treatment with other systemic cytostatics * Known medical history of severe decompensatoric cardiac insufficiency * Medical history of clinically unstable cardiac or pulmonary disease * Known or suspected hypersensitivity to azacitidine or mannitol